BDI Pharma, Inc. (Formerly known as Blood Diagnostics, Inc.)'s Specialty Biotherapeutics Sales Outpace Expectations

COLUMBIA, SC--(Marketwire - October 21, 2009) -

BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced that revenue for the third quarter of 2009 continued to sustain the momentum experienced during the first two fiscal quarters of this year. A primary driver of third quarter revenue was the exceptional success of the company’s expanded portfolio of specialty biotherapeutics.

“During Q3 2009, BDI Pharma celebrated completion of the first twelve (12) months of the most significant product portfolio expansion in the company’s history,” said William A. Shirey, III, Executive Vice President. “BDI Pharma is an organization founded on a customer-centric service model, and as such, since our inception in 1995, we have been repeatedly asked by our customers to provide additional specialty pharmaceuticals to complement the plasma protein therapy products that historically comprised the company’s core business. Due to the initial positive response to these supplemental product lines, we revised our revenue projections upward after the first six months; however, sales uptake continued at such a pace that the final revenue numbers represented more than a fifty percent (50%) increase over those revised expectations.”

Edward Steres, Vice President of Strategic Partnerships, stated, “During this same period, as BDI Pharma enhanced its product portfolio, we have established relationships with a number of innovative biotech and pharmaceutical manufacturers. These cutting-edge organizations now acknowledge BDI Pharma as an authorized distributor of record for their products, and as we forge ahead adding drugs to treat additional disease states, we will continue to cultivate relationships with the strategic addition of new limited distribution partnerships.”

About BDI Pharma, Inc.

Serving the healthcare community since 1995, BDI Pharma, Inc. has built an outstanding reputation as an industry source for products and service. BDI Pharma’s market focus is evident in its commitment to specialty biotherapeutics, chemotherapies, vaccines and plasma protein therapies, including Albumin, intravenous immune globulin (IVIG or IGIV), coagulation factors VIII, IX, and VIIa, hyper-immunes, and injectables. As a manufacturer recognized Authorized Distributor of Record, BDI Pharma, Inc. services the entire country and is fully accredited and insured, fulfilling the licensing requirements in all 50 states.

In an arena where access to pertinent clinical data and updated information on market availability is paramount to patient care, BDI Pharma, Inc. defines its customer-centric approach to serving the nation’s healthcare community through innovative inventory management programs, unparalleled customer service, extensive product knowledge, unique promotional services, emergency availability and urgent need delivery. The company serves as a source for reference material and market data, offering healthcare providers the latest information on products, supply and other industry events. BDI Pharma, Inc.'s educational literature and Web site -- www.bdipharma.com -- serve as open-access resources, contributing to the promotion of the biopharmaceutical industry and the education of both the healthcare community and general populace.